225000
22381742
23113000
1678220
1700000
43923
15.00
21841742
21841742
200000000
0
0
0
0
0.001
5000000
0.001
0.001
0
0
5372000
0
22000
2889000
-80143000
2483000
101611000
187000
106983000
181732000
710000
0
5372000
571000
105464000
38000
1260000
200000
106983000
5073000
21000
106724000
1015000
91311000
0
3
0
1470902
43923
15.00
11691000
493292
493292
173018331
155586141
0
155586141
155586141
0.001
0
0.001
0.001
0
85345000
83528
0
2209000
0
5000
-63055000
2204000
-55267000
60000
32287000
7788000
338000
0
2209000
436000
31753000
29000
24402000
425000
50000
30000
32287000
32178000
1370000
1311000
30000
0
1590580
1800000
450000
0.095
14860173
6480000
3306000
90396000
540000
540000
7533000
0.04
0.01
-8655000
390001
-26.36
13550083
10000
30000
180000
-10200000
19000
-10279000
-10200000
137000
10200000
7852000
11422000
79000
7000
20126000
19921000
1414000
-49000
215000
265000
2348000
167000
137000
12487660
1062423
50000
0.10
10000
82000
55000
59000
<div>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b>3. Accrued Expenses</b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
Accrued expenses consisted of the following:</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
<tr>
<td width="72%"></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>September 30,<br />
2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December 31,<br />
2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Accrued research and development expenses</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">1,015</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">1,370</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Accrued payroll and related expenses</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">571</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">436</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Accrued professional fees</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">710</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">338</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Accrued other</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">187</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">60</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
<td valign="top"></td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">2,483</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">2,204</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
</tr>
</table>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
<b>7. Commitments and Contingencies</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
<b><i>Leases</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
The Company leases its office space and obtains certain
office-related services on a month-to-month basis under a 30-day
cancelable operating service agreement. Payments under this service
agreement include monthly rent and certain fee-for-service
charges.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
During the three months ended September 30, 2014 and 2013, the
Company recognized $152 and $92, respectively, of rental expense
related to office space. During the nine months ended
September 30, 2014 and 2013, the Company recognized $361 and
$265, respectively, of rental expense related to office space.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
<b><i>Intellectual Property Licenses</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
The Company has a master license agreement, dated May 19,
2006, with the University of Maryland, Baltimore
(“UMB”), as amended by First Amendment, dated as of
March 3, 2009, Second Amendment, dated as of April 10,
2012, and Third Amendment, dated as of October 28, 2013 (the
“license agreement”). Pursuant to the license
agreement, UMB granted an exclusive worldwide license, with the
right to sublicense, under certain patents and patent applications
to make, have made, use, sell, offer to sell and import certain
anti-androgen steroids including galeterone for the prevention,
diagnosis, treatment or control of any human or animal disease. In
addition, UMB granted the Company a first option to receive an
exclusive license to UMB’s rights in certain improvements to
the licensed products. The Company has exercised the option and
acquired exclusive rights to licensed improvements under three
amendments to the license agreement.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
The Company is obligated to pay UMB an annual maintenance fee of
$10 each year until the first commercial sale of a product
developed using the licensed technology. The Company is also
obligated to make an additional $50 milestone payment to UMB for
each additional investigational new drug application filed for a
licensed product and a $100 milestone payment upon the approval of
each new drug application for a licensed product by the U.S. Food
and Drug Administration. Because the achievement of these
milestones has not occurred as of December 31, 2013 or
September 30, 2014, no liabilities for such milestone payments
have been recorded in the Company’s consolidated financial
statements.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
The Company must also pay UMB low-single-digit percentage royalties
on aggregate worldwide net sales of licensed products, including
sales by sublicensees, on a licensed product-by-licensed product
and country-by-country basis until the later of the expiration of
the last-to-expire applicable licensed patent or ten years after
first commercial sale of the applicable licensed product, in each
case in the applicable country. The royalty obligations are subject
to specified reductions in the event that additional licenses need
to be obtained from third parties or in the event of specified
competition from third-party products licensed by UMB. Minimum
annual royalty payments to UMB are $50 beginning in the year
following the year in which the first commercial sale occurs. The
Company must also pay UMB 10% of all non-royalty sublicense income
received from sublicensees. Finally, the Company is responsible for
all patent expenses related to the prosecution and maintenance of
the licensed patents. As of December 31, 2013 and
September 30, 2014, the Company has not yet developed a
commercial product using the licensed technologies, and it has not
entered into any sublicense agreements for the technologies. In
connection with this license agreement, the Company incurred no
license, milestone or maintenance fees for the three months ended
September 30, 2014 or 2013. In connection with this license
agreement, the Company incurred license, milestone and maintenance
fees of $10 in each of the nine month periods ended
September 30, 2014 and 2013.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
<b><i>Advisor Agreement</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
The Company was obligated to pay a fee to a financial advisor of
$1,053 upon the closing of the IPO of the Company’s shares of
common stock in connection with strategic and financial advisory
services unrelated to the IPO. As of September 30, 2014, the
Company had recorded general and administrative expense of $1,053
related to this payment.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
<b><i>Indemnification Agreements</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
In the ordinary course of business, the Company may provide
indemnification of varying scope and terms to vendors, lessors,
business partners, and other parties with respect to certain
matters including, but not limited to, losses arising out of breach
of such agreements or from intellectual property infringement
claims made by third parties.</p>
<p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 </p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
In addition, the Company has entered into indemnification
agreements with each of its directors and executive officers, which
provide, among other things, that the Company will indemnify such
directors and executive officers to the fullest extent permitted by
law for claims arising in his or her capacity as a director or
officer. The maximum potential amount of future payments the
Company could be required to make under these indemnification
agreements is, in many cases, unlimited</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
To date, the Company has not incurred any material costs as a
result of the indemnification agreements described above. The
Company does not believe that the outcome of any claims under
indemnification arrangements will have a material effect on its
financial position, results of operations or cash flows, and it has
not accrued any liabilities related to such obligations in its
financial statements as of December 31, 2013 or
September 30, 2014.</p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Net Income (Loss) Per Share</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
In September 2014, upon the closing of the IPO, all of the
outstanding shares of the Company’s redeemable convertible
preferred stock automatically converted into 14,860,173 shares of
the Company’s common stock. Prior to this conversion, the
Company followed the two-class method when computing net income
(loss) per share as the Company had issued shares that met the
definition of participating securities. The two-class method
determines net income (loss) per share for each class of common and
participating securities according to dividends declared or
accumulated and participation rights in undistributed earnings. The
two-class method requires income available to common stockholders
for the period to be allocated between common and participating
securities based upon their respective rights to receive dividends
as if all income for the period had been distributed. The
Company’s redeemable convertible preferred stock
contractually entitled the holders of such shares to participate in
dividends, but did not contractually require the holders of such
shares to participate in losses of the Company. Accordingly, the
two-class method did not apply for periods in which the Company
reported a net loss or a net loss attributable to common
stockholders resulting from dividends or accretion related to its
redeemable convertible preferred stock.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
Basic net income (loss) per share attributable to common
stockholders is computed by dividing the net income (loss)
attributable to common stockholders by the weighted average number
of common shares outstanding for the period. Diluted net income
(loss) per share attributable to common stockholders is computed by
dividing the diluted net income (loss) attributable to common
stockholders by the weighted average number of common shares,
including potential dilutive common shares assuming the dilutive
effect of outstanding stock options and unvested restricted common
shares, as determined using the treasury stock method. For periods
in which the Company has reported net losses, diluted net loss per
common share attributable to common stockholders is the same as
basic net loss per common share attributable to common
stockholders, since dilutive common shares are not assumed to have
been issued if their effect is anti-dilutive.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The Company reported a net loss attributable to common stockholders
for the three and nine months ended September 30, 2014 and
2013.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The following common stock equivalents outstanding as of
September 30, 2014 and 2013 were excluded from the computation
of diluted net loss per share for the three and nine months ended
September 30, 2014 and 2013, because they had an anti-dilutive
impact:</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
<tr>
<td width="75%"></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As of September 30,</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Options to purchase common stock</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,852,709</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,062,423</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Restricted common stock units</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">54,604</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap"> </td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Redeemable convertible preferred stock</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap"> </td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">12,487,660</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Option to purchase additional shares of common stock granted to the
underwriters in connection with the IPO</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">972,000</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap"> </td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Total options, restricted stock units and redeemable convertible
preferred stock exercisable or convertible into common stock</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">2,879,313</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">13,550,083</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
In connection with the IPO, the Company granted the underwriters an
option to purchase up to 972,000 additional shares of the
Company’s common stock for a period of 30 days from
September 16, 2014, which is reflected in the table above. As
noted in Note 10, the Company issued and sold 540,000 shares of its
common stock in October 2014 pursuant to the underwriters’
partial exercise of their option to purchase additional shares of
common stock.</p>
</div>
10-Q
TOKAI PHARMACEUTICALS INC
TKAI
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
<b><i>Comprehensive Loss</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
Comprehensive loss includes net loss as well as other changes in
stockholders’ equity (deficit) that result from transactions
and economic events other than those with stockholders. For the
three and nine months ended September 30, 2014 and 2013, there
was no difference between net loss and comprehensive loss.</p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
<b><i>Income Taxes</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
The Company accounts for income taxes using the asset and liability
method, which requires the recognition of deferred tax assets and
liabilities for the expected future tax consequences of events that
have been recognized in the consolidated financial statements or in
the Company’s tax returns. Deferred taxes are determined
based on the difference between the financial statement and tax
basis of assets and liabilities using enacted tax rates in effect
in the years in which the differences are expected to reverse.
Changes in deferred tax assets and liabilities are recorded in the
provision for income taxes. The Company assesses the likelihood
that its deferred tax assets will be recovered from future taxable
income and, to the extent it believes, based upon the weight of
available evidence, that it is more likely than not that all or a
portion of deferred tax assets will not be realized, a valuation
allowance is established through a charge to income tax expense.
Potential for recovery of deferred tax assets is evaluated by
estimating the future taxable profits expected and considering
prudent and feasible tax planning strategies.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
The Company accounts for uncertainty in income taxes recognized in
the consolidated financial statements by applying a two-step
process to determine the amount of tax benefit to be recognized.
First, the tax position must be evaluated to determine the
likelihood that it will be sustained upon external examination by
the taxing authorities. If the tax position is deemed
more-likely-than-not to be sustained, the tax position is then
assessed to determine the amount of benefit to recognize in the
consolidated financial statements. The amount of the benefit that
may be recognized is the largest amount that has a greater than 50%
likelihood of being realized upon ultimate settlement. The
provision for income taxes includes the effects of any resulting
tax reserves, or unrecognized tax benefits, that are considered
appropriate as well as the related net interest and penalties.</p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The following common stock equivalents outstanding as of
September 30, 2014 and 2013 were excluded from the computation
of diluted net loss per share for the three and nine months ended
September 30, 2014 and 2013, because they had an anti-dilutive
impact:</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
<tr>
<td width="75%"></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As of September 30,</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Options to purchase common stock</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,852,709</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,062,423</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Restricted common stock units</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">54,604</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap"> </td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Redeemable convertible preferred stock</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap"> </td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">12,487,660</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Option to purchase additional shares of common stock granted to the
underwriters in connection with the IPO</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">972,000</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap"> </td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Total options, restricted stock units and redeemable convertible
preferred stock exercisable or convertible into common stock</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">2,879,313</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">13,550,083</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
</tr>
</table>
<br class="Apple-interchange-newline" /></div>
Non-accelerated Filer
P3Y6M
-14661000
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>9. Related Party Transactions</b></p>
<!-- xbrl,body -->
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
The Company has an outstanding loan to a former advisor and
stockholder that has been fully reserved for by the Company. As of
December 31, 2013, no payments had been received by the
Company, and the unpaid principal and interest balance remained
fully reserved. Subsequent to December 31, 2013, the Company
started to receive repayment of this note. The Company is recording
payments received as other income in 2014 as cash is received. As a
result, the Company recorded other income of $34 and $113 for the
three and nine months ended September 30, 2014, representing
cash collected by the Company during those periods.</p>
</div>
The Company effected a 1-for-10.47 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of redeemable convertible preferred stock.
<div>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
Accrued expenses consisted of the following:</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
<tr>
<td width="72%"></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>September 30,<br />
2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December 31,<br />
2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Accrued research and development expenses</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">1,015</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">1,370</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Accrued payroll and related expenses</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">571</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">436</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Accrued professional fees</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">710</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">338</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Accrued other</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">187</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">60</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
<td valign="top"></td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">2,483</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">2,20</td>
</tr>
</table>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
<b><i>Use of Estimates</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
The preparation of financial statements in conformity with GAAP
requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities, the disclosure of
contingent assets and liabilities at the date of the consolidated
financial statements, and the reported amounts of expenses during
the reporting periods. Significant estimates and assumptions
reflected in these consolidated financial statements include, but
are not limited to, the accrual of research and development
expenses and the valuation of common stock, redeemable convertible
preferred stock and stock-based awards. Estimates are periodically
reviewed in light of changes in circumstances, facts and
experience. Actual results could differ from the Company’s
estimates.</p>
</div>
1124627
2014-09-30
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
<b><i>Cash Equivalents</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
The Company considers all short-term, highly liquid investments
with original maturities of ninety days or less at date of purchase
to be cash equivalents. Cash equivalents, which consist of money
market accounts, are stated at fair value.</p>
</div>
P30D
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
<b><i>Property and Equipment</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
Property and equipment are stated at cost less accumulated
depreciation. Depreciation expense is recognized using the
straight-line method over a three-year estimated useful life for
computer equipment, which is the only type of property and
equipment the Company holds. Expenditures for repairs and
maintenance of assets are charged to expense as incurred. Upon
retirement or sale, the cost and related accumulated depreciation
of assets disposed of are removed from the accounts and any
resulting gain or loss is included in loss from operations.</p>
</div>
P3Y
<div>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Research and Development Costs</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
Research and development costs are expensed as incurred. Included
in research and development expenses are salaries, stock-based
compensation and benefits of employees, third-party license fees
and other operational costs related to the Company’s research
and development activities, including manufacturing expenses and
external costs of outside vendors engaged to conduct both
preclinical studies and clinical trials.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The Company has entered into various research and development
contracts with research institutions and other companies both
inside and outside of the United States. These agreements are
generally cancelable, and related payments are recorded as research
and development expenses as incurred. The Company records accruals
for estimated ongoing costs. This process involves reviewing open
contracts and purchase orders, communicating with personnel to
identify services that have been performed and estimating the level
of service performed and the associated costs incurred for the
services for which the Company has not yet been invoiced.
Significant judgments and estimates are made in determining the
accrued balances at the end of any reporting period. Actual results
could differ from the Company’s estimates. The
Company’s historical accrual estimates have not been
materially different from the actual costs.</p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b>4. Redeemable Convertible Preferred Stock and
Stockholders’ Equity (Deficit)</b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
On August 29, 2014, the Company effected a 1-for-10.47 reverse
stock split of its issued and outstanding shares of common stock
and a proportional adjustment to the existing conversion ratios for
each series of redeemable convertible preferred stock. Accordingly,
all share and per share amounts for all periods presented in these
consolidated financial statements and notes thereto have been
adjusted retroactively, where applicable, to reflect this reverse
stock split and adjustment of the redeemable convertible preferred
stock conversion ratios.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
On September 22, 2014, the Company completed its IPO and
issued and sold 6,480,000 shares of common stock at a public
offering price of $15.00 per share, resulting in net proceeds of
approximately $90,396 after deducting underwriting discounts and
commissions but before the payment of estimated offering expenses
of $3,306.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
Upon the closing of the IPO, all outstanding shares of the
Company’s redeemable convertible preferred stock
automatically converted into 14,860,173 shares of the
Company’s common stock.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
As of September 30, 2014 the Company’s Certificate of
Incorporation, as amended and restated, authorizes the Company to
issue 5,000,000 shares of preferred stock, $0.001 par value.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
As of September 30, 2014 and December 31, 2013, the
Company’s Certificate of Incorporation, as amended and
restated, authorizes the Company to issue 200,000,000 and
173,018,331 shares, respectively, of common stock, $0.001 par
value.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 18pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 </p>
</div>
false
--12-31
2014
<div>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b>1. Nature of the Business and Basis of Presentation</b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
Tokai Pharmaceuticals, Inc. (the “Company”) was
incorporated on March 26, 2004 under the laws of the State of
Delaware. The Company is a clinical-stage biopharmaceutical company
focused on developing novel proprietary therapies for the treatment
of prostate cancer and other hormonally-driven diseases. The
Company’s lead drug candidate, galeterone, is a highly
selective, multi-targeted, oral small molecule drug candidate.
Since its inception, the Company has devoted substantially all of
its efforts to research and development, recruiting management,
in-licensing technology and raising capital.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The Company was previously classified as a “development stage
entity” in the Accounting Standards Codification and, as
such, was required to present inception-to-date information in the
Company’s statements of operations and comprehensive loss,
redeemable convertible preferred stock and stockholders’
deficit, and cash flows. In June 2014, the Financial Accounting
Standards Board (“FASB”) issued an accounting standards
update that eliminates the concept of a development stage entity
from U.S. generally accepted accounting principles and removes the
related incremental reporting requirements. See Note 2 below for
additional information on this new standard. The Company elected to
early adopt the new standard in the three months ended
September 30, 2014. Accordingly, in contrast to the
Company’s financial statements and the notes thereto for the
year ended December 31, 2013 included in Company’s
Registration Statement on Form S-1 on file with the Securities and
Exchange Commission (“SEC”), the financial statements
contained in this report do not include inception-to-date
information.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The Company is subject to risks common to companies in the
biotechnology industry including, but not limited to, new
technological innovations, protection of proprietary technology,
dependence on key personnel, compliance with government regulations
and the need to obtain additional financing. Galeterone, which is
currently under development, and any product candidates that the
Company may seek to develop in the future will require significant
additional research and development efforts, including extensive
preclinical and clinical testing and regulatory approval, prior to
commercialization. These efforts require significant amounts of
additional capital, adequate personnel infrastructure, and
extensive compliance-reporting capabilities.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
There can be no assurance that the Company’s research and
development will be successfully completed, that adequate
protection for the Company’s intellectual property will be
obtained, that any products developed will obtain necessary
government regulatory approval or that any approved products will
be commercially viable. Even if the Company’s drug
development efforts are successful, it is uncertain when, if ever,
the Company will generate significant revenue from product sales.
The Company operates in an environment of rapid change in
technology and substantial competition from pharmaceutical and
biotechnology companies. In addition, the Company is dependent upon
the services of its employees and consultants.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The accompanying consolidated financial statements and footnotes
include Diotima Pharmaceuticals, Inc. (“Diotima”), a
variable interest entity in which the Company had a variable
financial interest and was the primary beneficiary but had no
ownership interest. In 2010, the Company formed and incorporated
Diotima. Diotima operated as a stand-alone company with limited
activity through April 2014. In early 2014, the license agreements
relating to the Diotima compounds were terminated. Additionally, in
April 2014, the board of directors and stockholders of Diotima
approved the dissolution of Diotima, and Diotima was dissolved.
Expenses incurred by Diotima for the three and nine months ended
September 30, 2014 were $0 and $8, respectively, and for the
three and nine months ended September 30, 2013, were $1 and
$59, respectively. All significant intercompany balances and
transactions between the Company and Diotima have been eliminated
in consolidation.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
On September 22, 2014, the Company completed an initial public
offering (“IPO”) of its common stock, and issued and
sold 6,480,000 shares of common stock at a public offering price of
$15.00 per share, resulting in net proceeds of approximately
$90,396 after deducting underwriting discounts and commissions but
before the payment of estimated offering expenses of $3,306. Upon
the closing of the IPO, all outstanding shares of the
Company’s redeemable convertible preferred stock
automatically converted into 14,860,173 shares of the
Company’s common stock. On October 9, 2014, the Company
issued and sold an additional 540,000 shares of its common stock at
the IPO price of $15.00 per share, less underwriting discounts and
commissions, pursuant to the underwriters’ partial exercise
of their option to purchase additional shares of common stock,
resulting in additional net proceeds to the Company of
approximately $7,533 after deducting underwriting discounts and
commissions (Note 10).</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Unaudited Interim Financial Information</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The consolidated balance sheet at December 31, 2013 was
derived from audited financial statements, but does not include all
disclosures required by U.S. generally accepted accounting
principles (“GAAP”). The accompanying unaudited
consolidated financial statements as of September 30, 2014 and
for the three months and nine months ended September 30, 2014
and 2013 have been prepared by the Company, pursuant to the rules
and regulations of the SEC for interim financial statements.
Certain information and footnote disclosures normally included in
financial statements prepared in accordance with GAAP have been
condensed or omitted pursuant to such rules and regulations.
However, the Company believes that the disclosures are adequate to
make the information presented not misleading. These consolidated
financial statements should be read in conjunction with the
Company’s audited consolidated financial statements and the
notes thereto for the year ended December 31, 2013 included in
the Company’s Registration Statement on Form S-1, File Number
333-198052 on file with the SEC. In the opinion of management, all
adjustments, consisting only of normal recurring adjustments
necessary for a fair statement of the Company’s financial
position as of September 30, 2014 and consolidated results of
operations for the three and nine months ended September 30,
2014 and 2013 and cash flows for the nine months ended
September 30, 2014 and 2013 have been made. The results of
operations for the three and nine months ended September 30,
2014 are not necessarily indicative of the results of operations
that may be expected for the year ending December 31,
2014.</p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
<b><i>Deferred Offering Costs</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
The Company capitalizes certain legal, accounting and other
third-party fees that are directly associated with in-process
equity financings as other assets until such financings are
consummated. After consummation of the equity financing, these
costs are recorded in stockholders’ equity (deficit) as a
reduction of additional paid-in capital generated as a result of
the offering or as a reduction to the carrying value of preferred
stock issued. As of December 31, 2013, the Company had
recorded $30 of deferred offering costs, included in other assets
in the accompanying consolidated balance sheet in contemplation of
the Company’s IPO, which closed in September 2014. The
Company has no deferred offering costs as of September 30,
2014.</p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
<b>5. Income Taxes</b></p>
<!-- xbrl,body -->
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
The Company did not provide for any income taxes in any of the
three or nine month periods ended September 30, 2014 or 2013.
The Company had gross deferred tax assets of $24,402 at
December 31, 2013 which increased by approximately $6,800 at
September 30, 2014. The Company has provided a valuation
allowance for the full amount of its net deferred tax assets
because, at September 30, 2014 and December 31, 2013, it
was more likely than not that any future benefit from deductible
temporary differences and net operating loss and tax credit
carryforwards would not be realized.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
The Company has not recorded any amounts for unrecognized tax
benefits as of September 30, 2014 or December 31, 2013.
As of September 30, 2014 and December 31, 2013, the
Company had no accrued interest or tax penalties recorded. The
Company’s income tax return reporting periods since
December 31, 2011 are open to income tax audit examination by
the federal and state tax authorities. In addition, because the
Company has net operating loss carryforwards, the Internal Revenue
Service is permitted to audit earlier years and propose adjustments
up to the amount of net operating losses generated in those
years.</p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b>2. Summary of Significant Accounting Policies</b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Use of Estimates</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The preparation of financial statements in conformity with GAAP
requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities, the disclosure of
contingent assets and liabilities at the date of the consolidated
financial statements, and the reported amounts of expenses during
the reporting periods. Significant estimates and assumptions
reflected in these consolidated financial statements include, but
are not limited to, the accrual of research and development
expenses and the valuation of common stock, redeemable convertible
preferred stock and stock-based awards. Estimates are periodically
reviewed in light of changes in circumstances, facts and
experience. Actual results could differ from the Company’s
estimates.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Cash Equivalents</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The Company considers all short-term, highly liquid investments
with original maturities of ninety days or less at date of purchase
to be cash equivalents. Cash equivalents, which consist of money
market accounts, are stated at fair value.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Concentration of Credit Risk and of Significant
Suppliers</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
Financial instruments that potentially expose the Company to
concentrations of credit risk consist primarily of cash and cash
equivalents. The Company has all cash and cash equivalents balances
at one accredited financial institution, in amounts that exceed
federally insured limits. The Company does not believe that it is
subject to unusual credit risk beyond the normal credit risk
associated with commercial banking relationships.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The Company is dependent on third-party manufacturers to supply
products for research and development activities in its programs.
In particular, the Company relies and expects to continue to rely
on a small number of manufacturers to supply it with its
requirements for the active pharmaceutical ingredients and
formulated drugs related to these programs. These programs could be
adversely affected by a significant interruption in the supply of
active pharmaceutical ingredients and formulated drugs.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 18pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 </p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Fair Value Measurements</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
Certain assets and liabilities are carried at fair value under
GAAP. Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit
price) in the principal or most advantageous market for the asset
or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair
value must maximize the use of observable inputs and minimize the
use of unobservable inputs. Financial assets and liabilities
carried at fair value are to be classified and disclosed in one of
the following three levels of the fair value hierarchy, of which
the first two are considered observable and the last is considered
unobservable:</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="9%"> </td>
<td valign="top" width="3%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">Level 1—Quoted prices in active
markets for identical assets or liabilities.</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="9%"> </td>
<td valign="top" width="3%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">Level 2—Observable inputs
(other than Level 1 quoted prices) such as quoted prices in active
markets for similar assets or liabilities, quoted prices in markets
that are not active for identical or similar assets or liabilities,
or other inputs that are observable or can be corroborated by
observable market data.</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="9%"> </td>
<td valign="top" width="3%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">Level 3—Unobservable inputs
that are supported by little or no market activity and that are
significant to determining the fair value of the assets or
liabilities, including pricing models, discounted cash flow
methodologies and similar techniques.</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The Company’s cash equivalents of $91,311 and $1,311 as of
September 30, 2014 and December 31, 2013, respectively,
were carried at fair value based on Level 2 inputs. The carrying
values of accounts payable and accrued expenses approximate their
fair value due to the short-term nature of these liabilities.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Deferred Offering Costs</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The Company capitalizes certain legal, accounting and other
third-party fees that are directly associated with in-process
equity financings as other assets until such financings are
consummated. After consummation of the equity financing, these
costs are recorded in stockholders’ equity (deficit) as a
reduction of additional paid-in capital generated as a result of
the offering or as a reduction to the carrying value of preferred
stock issued. As of December 31, 2013, the Company had
recorded $30 of deferred offering costs, included in other assets
in the accompanying consolidated balance sheet in contemplation of
the Company’s IPO, which closed in September 2014. The
Company has no deferred offering costs as of September 30,
2014.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Property and Equipment</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
Property and equipment are stated at cost less accumulated
depreciation. Depreciation expense is recognized using the
straight-line method over a three-year estimated useful life for
computer equipment, which is the only type of property and
equipment the Company holds. Expenditures for repairs and
maintenance of assets are charged to expense as incurred. Upon
retirement or sale, the cost and related accumulated depreciation
of assets disposed of are removed from the accounts and any
resulting gain or loss is included in loss from operations.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Impairment of Long-Lived Assets</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
Long-lived assets consist of property and equipment. Long-lived
assets to be held and used are tested for recoverability whenever
events or changes in business circumstances indicate that the
carrying amount of the assets may not be fully recoverable. Factors
that the Company considers in deciding when to perform an
impairment review include significant underperformance of the
business in relation to expectations, significant negative industry
or economic trends, and significant changes or planned changes in
the use of the assets. If an impairment review is performed to
evaluate a long-lived asset for recoverability, the Company
compares forecasts of undiscounted cash flows expected to result
from the use and eventual disposition of the long-lived asset to
its carrying value. An impairment loss would be recognized when
estimated undiscounted future cash flows expected to result from
the use of an asset are less than its carrying amount. The
impairment loss would be based on the excess of the carrying value
of the impaired asset over its fair value, determined based on
discounted cash flows. To date, the Company has not recorded any
impairment losses on long-lived assets.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Research and Development Costs</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
Research and development costs are expensed as incurred. Included
in research and development expenses are salaries, stock-based
compensation and benefits of employees, third-party license fees
and other operational costs related to the Company’s research
and development activities, including manufacturing expenses and
external costs of outside vendors engaged to conduct both
preclinical studies and clinical trials.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The Company has entered into various research and development
contracts with research institutions and other companies both
inside and outside of the United States. These agreements are
generally cancelable, and related payments are recorded as research
and development expenses as incurred. The Company records accruals
for estimated ongoing costs. This process involves reviewing open
contracts and purchase orders, communicating with personnel to
identify services that have been performed and estimating the level
of service performed and the associated costs incurred for the
services for which the Company has not yet been invoiced.
Significant judgments and estimates are made in determining the
accrued balances at the end of any reporting period. Actual results
could differ from the Company’s estimates. The
Company’s historical accrual estimates have not been
materially different from the actual costs.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Patent Costs</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
All patent-related costs incurred in connection with filing and
prosecuting patent applications are recorded as general and
administrative expenses as incurred, as recoverability of such
expenditures is uncertain.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Accounting for Stock-Based Compensation</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The Company measures all stock options and other stock-based awards
granted to employees and directors at the fair value on the date of
the grant using the Black-Scholes option-pricing model. The fair
value of the awards is recognized as expense, net of estimated
forfeitures, over the requisite service period, which is generally
the vesting period of the respective award. The straight-line
method of expense recognition is applied to all awards with
service-only conditions, while the graded vesting method is applied
to all grants with both service and performance conditions.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
For stock-based awards granted to non-employees, compensation
expense is recognized over the period during which services are
rendered by such non-employees until completed. At the end of each
financial reporting period prior to completion of the service, the
fair value of these awards is remeasured using the then-current
fair value of the Company’s common stock and updated
assumption inputs in the Black-Scholes option-pricing model.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The Company classifies stock-based compensation expense in its
consolidated statement of operations and comprehensive loss in the
same manner in which the award recipient’s payroll costs are
classified or in which the award recipient’s service payments
are classified.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The Company recognizes compensation expense for only the portion of
awards that are expected to vest. In developing a forfeiture rate
estimate, the Company has considered its historical experience to
estimate pre-vesting forfeitures for service-based awards. The
impact of a forfeiture rate adjustment will be recognized in full
in the period of adjustment, and if the actual forfeiture rate is
materially different from the Company’s estimate, the Company
may be required to record adjustments to stock-based compensation
expense in future periods.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Income Taxes</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The Company accounts for income taxes using the asset and liability
method, which requires the recognition of deferred tax assets and
liabilities for the expected future tax consequences of events that
have been recognized in the consolidated financial statements or in
the Company’s tax returns. Deferred taxes are determined
based on the difference between the financial statement and tax
basis of assets and liabilities using enacted tax rates in effect
in the years in which the differences are expected to reverse.
Changes in deferred tax assets and liabilities are recorded in the
provision for income taxes. The Company assesses the likelihood
that its deferred tax assets will be recovered from future taxable
income and, to the extent it believes, based upon the weight of
available evidence, that it is more likely than not that all or a
portion of deferred tax assets will not be realized, a valuation
allowance is established through a charge to income tax expense.
Potential for recovery of deferred tax assets is evaluated by
estimating the future taxable profits expected and considering
prudent and feasible tax planning strategies.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The Company accounts for uncertainty in income taxes recognized in
the consolidated financial statements by applying a two-step
process to determine the amount of tax benefit to be recognized.
First, the tax position must be evaluated to determine the
likelihood that it will be sustained upon external examination by
the taxing authorities. If the tax position is deemed
more-likely-than-not to be sustained, the tax position is then
assessed to determine the amount of benefit to recognize in the
consolidated financial statements. The amount of the benefit that
may be recognized is the largest amount that has a greater than 50%
likelihood of being realized upon ultimate settlement. The
provision for income taxes includes the effects of any resulting
tax reserves, or unrecognized tax benefits, that are considered
appropriate as well as the related net interest and penalties.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 18pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 </p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Segment Data</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The Company manages its operations as a single segment for the
purposes of assessing performance and making operating decisions.
The Company’s singular focus is on developing novel
proprietary therapies for the treatment of prostate cancer and
other hormonally-driven diseases. No revenue has been generated
since inception, and all tangible assets are held in the United
States.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Comprehensive Loss</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
Comprehensive loss includes net loss as well as other changes in
stockholders’ equity (deficit) that result from transactions
and economic events other than those with stockholders. For the
three and nine months ended September 30, 2014 and 2013, there
was no difference between net loss and comprehensive loss.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Net Income (Loss) Per Share</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
In September 2014, upon the closing of the IPO, all of the
outstanding shares of the Company’s redeemable convertible
preferred stock automatically converted into 14,860,173 shares of
the Company’s common stock. Prior to this conversion, the
Company followed the two-class method when computing net income
(loss) per share as the Company had issued shares that met the
definition of participating securities. The two-class method
determines net income (loss) per share for each class of common and
participating securities according to dividends declared or
accumulated and participation rights in undistributed earnings. The
two-class method requires income available to common stockholders
for the period to be allocated between common and participating
securities based upon their respective rights to receive dividends
as if all income for the period had been distributed. The
Company’s redeemable convertible preferred stock
contractually entitled the holders of such shares to participate in
dividends, but did not contractually require the holders of such
shares to participate in losses of the Company. Accordingly, the
two-class method did not apply for periods in which the Company
reported a net loss or a net loss attributable to common
stockholders resulting from dividends or accretion related to its
redeemable convertible preferred stock.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
Basic net income (loss) per share attributable to common
stockholders is computed by dividing the net income (loss)
attributable to common stockholders by the weighted average number
of common shares outstanding for the period. Diluted net income
(loss) per share attributable to common stockholders is computed by
dividing the diluted net income (loss) attributable to common
stockholders by the weighted average number of common shares,
including potential dilutive common shares assuming the dilutive
effect of outstanding stock options and unvested restricted common
shares, as determined using the treasury stock method. For periods
in which the Company has reported net losses, diluted net loss per
common share attributable to common stockholders is the same as
basic net loss per common share attributable to common
stockholders, since dilutive common shares are not assumed to have
been issued if their effect is anti-dilutive.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The Company reported a net loss attributable to common stockholders
for the three and nine months ended September 30, 2014 and
2013.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The following common stock equivalents outstanding as of
September 30, 2014 and 2013 were excluded from the computation
of diluted net loss per share for the three and nine months ended
September 30, 2014 and 2013, because they had an anti-dilutive
impact:</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
<tr>
<td width="75%"></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As of September 30,</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Options to purchase common stock</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,852,709</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,062,423</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Restricted common stock units</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">54,604</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap"> </td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Redeemable convertible preferred stock</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap"> </td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">12,487,660</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Option to purchase additional shares of common stock granted to the
underwriters in connection with the IPO</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">972,000</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom" nowrap="nowrap"> </td>
<td valign="bottom" nowrap="nowrap" align="right">
—  </td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Total options, restricted stock units and redeemable convertible
preferred stock exercisable or convertible into common stock</p>
</td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">2,879,313</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">13,550,083</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
In connection with the IPO, the Company granted the underwriters an
option to purchase up to 972,000 additional shares of the
Company’s common stock for a period of 30 days from
September 16, 2014, which is reflected in the table above. As
noted in Note 10, the Company issued and sold 540,000 shares of its
common stock in October 2014 pursuant to the underwriters’
partial exercise of their option to purchase additional shares of
common stock.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 18pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 </p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Recently Issued and Adopted Accounting
Pronouncements</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
In June 2014, the FASB issued Accounting Standards Update
No. 2014-10, <i>Development Stage Entities
(Topic 915): Elimination of Certain Financial Reporting
Requirements, Including an Amendment to Variable Interest Entities
Guidance in Topic 810, Consolidation</i>. The amendments in this
guidance remove all incremental financial reporting requirements
for development stage entities. Among other changes, this
guidance will no longer require development stage entities to
present inception-to-date information about income statement line
items, cash flows, and equity transactions. This guidance is
effective for public companies in the first annual period beginning
after December 15, 2014 with early adoption
permitted. The Company elected to apply this disclosure
guidance to its financial statements for the three months ended
September 30, 2014 and as a result, no longer discloses
inception-to-date information in its statements of operations and
comprehensive loss, cash flows and stockholders’ deficit and
the related notes thereto.</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
In August 2014, the FASB issued ASU 2014-15, <i>Presentation of Financial
Statements — Going Concern</i> (<i>Subtopic
205-40).</i> The
new guidance addresses management’s responsibility to
evaluate whether there is substantial doubt about an entity’s
ability to continue as a going concern and to provide related
footnote disclosures. Management’s evaluation should be based
on relevant conditions and events that are known and reasonably
knowable at the date that the financial statements are issued. The
standard will be effective for the first interim period within
annual reporting periods beginning after December 15, 2016.
Early adoption is permitted. The Company is evaluating the effect
that this guidance will have on its consolidated financial
statements.</p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>10. Subsequent Events</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
In connection with the IPO, on October 9, 2014, the Company
issued and sold an additional 540,000 shares of its common stock at
the IPO price of $15.00 per share, less underwriting discounts and
commissions, pursuant to the underwriters’ partial exercise
of their option to purchase additional shares of common stock,
resulting in additional net proceeds to the Company of
approximately $7,533 after deducting underwriting discounts and
commissions.</p>
</div>
0001404281
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>6. Stock-Based Awards</b></p>
<!-- xbrl,body -->
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
<b><i>2007 Stock Incentive Plan</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
Under the Company’s 2007 Stock Incentive Plan, as amended
(the “2007 Plan”), the Company was authorized to grant
options, restricted stock, restricted stock units and other
stock-based awards to the Company’s employees, officers,
directors, consultants and advisors. As of December 31, 2013,
a total of 1,590,580 shares of common stock were reserved for
issuance under the 2007 Plan. The Company’s 2014 Stock
Incentive Plan (the “2014 Plan”) became effective upon
effectiveness of the registration statement for the IPO on
September 12, 2014. Upon the effectiveness of the 2014 Plan,
43,923 shares of common stock that remained available for grant
under the 2007 Plan became available for grant under the 2014 Plan,
and no further awards were available to be issued under the 2007
Plan.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
<b><i>2014 Stock Incentive Plan</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
In August 2014, the Company’s board of directors and
stockholders approved the 2014 Plan, which became effective upon
effectiveness of the registration statement for the IPO on
September 12, 2014. Under the 2014 Plan, the Company may grant
incentive stock options, nonstatutory stock options, restricted
stock, restricted stock units, stock appreciation rights and other
stock-based awards to the Company’s employees, officers,
directors, consultants and advisors; however, incentive stock
options may only be granted to the Company’s employees. The
number of shares reserved for issuance under the 2014 Plan is equal
to the sum of (1) 1,700,000 shares of common stock, plus
(2) the number of shares (up to 1,678,220 shares) equal to the
sum of (i) 43,923 shares of common stock, which is the number
of shares reserved for issuance under the 2007 Plan that remained
available for grant under the 2007 Plan immediately prior to the
effectiveness of the 2014 Plan, and (ii) the number of shares
of common stock subject to outstanding awards under the 2007 Plan
that expire, terminate or are otherwise surrendered, cancelled,
forfeited or repurchased by the Company at their original issuance
price pursuant to a contractual repurchase right, plus (3) an
annual increase, to be added on the first day of each fiscal year,
beginning with the fiscal year ending December 31, 2015 and
continuing for each fiscal year until, and including, the fiscal
year ending December 31, 2024, equal to the least of 1,800,000
shares of the Company’s common stock, 4% of the number of
shares of the Company’s common stock outstanding on the first
day of the applicable fiscal year and an amount determined by the
Company’s board of directors.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
As required by the 2007 Plan and 2014 Plan, the exercise price for
stock options granted is not to be less than the fair value of
common stock as of the date of grant. Prior to the IPO, the value
of common stock was determined by the Company’s board of
directors by taking into consideration its most recently available
valuation of common stock performed by management and the board of
directors as well as additional factors which might have changed
since the date of the most recent contemporaneous valuation through
the date of grant.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
For the three months ended September 30, 2014, the Company
granted an employee a stock option to purchase 218,417 shares of
its common stock and a restricted stock unit for 54,604 shares of
common stock. The Company did not grant any other equity awards
during the three months ended September 30, 2014. As of
September 30, 2014, 1,470,902 shares remained available for
issuance under the 2014 Plan.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt">
<b><i>2014 Employee Stock Purchase Plan</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
In August 2014, the Company’s board of directors and
stockholders approved the 2014 Employee Stock Purchase Plan (the
“ESPP”), which became effective upon effectiveness of
the registration statement for the IPO on September 12, 2014.
An aggregate of 225,000 shares of the Company’s common stock
are reserved for issuance under the ESPP. The number of shares of
the Company’s common stock reserved for issuance under the
ESPP will automatically increase on the first day of each fiscal
year, commencing on January 1, 2015 and ending on
December 31, 2024, in an amount equal to the least of
(1) 450,000 shares of the Company’s common stock,
(2) 1% of the total number of shares of the Company’s
common stock outstanding on the first day of the applicable fiscal
year and (3) an amount determined by the Company’s board
of directors.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
<b><i>Stock Option Valuation</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
The fair value of each stock option grant is estimated on the date
of grant using the Black-Scholes option-pricing model. Prior to its
IPO, the Company was a private company and lacked company-specific
historical and implied volatility information. Therefore, the
Company estimated its expected stock volatility based on the
historical volatility of a publicly traded group of peer companies.
The Company expects to continue to do so until such time as it has
adequate historical data regarding the volatility of its own traded
stock price. The expected term of the Company’s stock options
has been determined utilizing the “simplified” method
for awards that qualify as “plain-vanilla” options. The
expected term of stock options granted to non-employees is equal to
the contractual term of the option award. The risk-free interest
rate is determined by reference to the U.S. Treasury yield
curve in effect at the time of grant of the award for time periods
approximately equal to the expected term of the award. Expected
dividend yield is based on the fact that the Company has never paid
cash dividends and does not expect to pay any cash dividends in the
foreseeable future.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
<b><i>Stock-based Compensation</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
The Company recorded stock-based compensation expense related to
stock options and restricted common stock in the following expense
categories of its statements of operations:</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"><!-- Begin Table Head -->
<tr>
<td width="75%"></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months<br />
Ended<br />
September 30,</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months<br />
Ended<br />
September 30,</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
<td valign="bottom"> </td>
</tr>
<!-- End Table Head --><!-- Begin Table Body -->
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Research and development</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">186</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">14</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">322</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">55</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
General and administrative</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">993</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">33</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,197</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">82</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top"></td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">1,179</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">47</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">1,519</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">137</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
</tr>
<!-- End Table Body --></table>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
Stock-based compensation expense for the three and nine months
ended September 30, 2014 includes $880 of stock-based
compensation expense related to a performance-based option grant
which vested during the three months ended September 30, 2014.
As of September 30, 2014, the Company had an aggregate of
$5,073 of unrecognized stock-based compensation cost, which is
expected to be recognized over a weighted average period of 3.5
years.</p>
</div>
-15.19
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
<b><i>Impairment of Long-Lived Assets</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
Long-lived assets consist of property and equipment. Long-lived
assets to be held and used are tested for recoverability whenever
events or changes in business circumstances indicate that the
carrying amount of the assets may not be fully recoverable. Factors
that the Company considers in deciding when to perform an
impairment review include significant underperformance of the
business in relation to expectations, significant negative industry
or economic trends, and significant changes or planned changes in
the use of the assets. If an impairment review is performed to
evaluate a long-lived asset for recoverability, the Company
compares forecasts of undiscounted cash flows expected to result
from the use and eventual disposition of the long-lived asset to
its carrying value. An impairment loss would be recognized when
estimated undiscounted future cash flows expected to result from
the use of an asset are less than its carrying amount. The
impairment loss would be based on the excess of the carrying value
of the impaired asset over its fair value, determined based on
discounted cash flows. To date, the Company has not recorded any
impairment losses on long-lived assets.</p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt">
<b><i>Recently Issued and Adopted Accounting
Pronouncements</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
In June 2014, the FASB issued Accounting Standards Update
No. 2014-10, <i>Development Stage Entities (Topic 915):
Elimination of Certain Financial Reporting Requirements, Including
an Amendment to Variable Interest Entities Guidance in Topic 810,
Consolidation</i>. The amendments in this guidance remove all
incremental financial reporting requirements for development stage
entities. Among other changes, this guidance will no longer
require development stage entities to present inception-to-date
information about income statement line items, cash flows, and
equity transactions. This guidance is effective for public
companies in the first annual period beginning after
December 15, 2014 with early adoption permitted. The
Company elected to apply this disclosure guidance to its financial
statements for the three months ended September 30, 2014 and
as a result, no longer discloses inception-to-date information in
its statements of operations and comprehensive loss, cash flows and
stockholders’ deficit and the related notes thereto.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
In August 2014, the FASB issued ASU 2014-15, <i>Presentation of
Financial Statements — Going Concern</i> (<i>Subtopic
205-40).</i> The new guidance addresses management’s
responsibility to evaluate whether there is substantial doubt about
an entity’s ability to continue as a going concern and to
provide related footnote disclosures. Management’s evaluation
should be based on relevant conditions and events that are known
and reasonably knowable at the date that the financial statements
are issued. The standard will be effective for the first interim
period within annual reporting periods beginning after
December 15, 2016. Early adoption is permitted. The Company is
evaluating the effect that this guidance will have on its
consolidated financial statements.</p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt">
<b><i>Segment Data</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
The Company manages its operations as a single segment for the
purposes of assessing performance and making operating decisions.
The Company’s singular focus is on developing novel
proprietary therapies for the treatment of prostate cancer and
other hormonally-driven diseases. No revenue has been generated
since inception, and all tangible assets are held in the United
States.</p>
</div>
14860173
Q3
0.00
2879313
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
<b><i>Concentration of Credit Risk and of Significant
Suppliers</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
Financial instruments that potentially expose the Company to
concentrations of credit risk consist primarily of cash and cash
equivalents. The Company has all cash and cash equivalents balances
at one accredited financial institution, in amounts that exceed
federally insured limits. The Company does not believe that it is
subject to unusual credit risk beyond the normal credit risk
associated with commercial banking relationships.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
The Company is dependent on third-party manufacturers to supply
products for research and development activities in its programs.
In particular, the Company relies and expects to continue to rely
on a small number of manufacturers to supply it with its
requirements for the active pharmaceutical ingredients and
formulated drugs related to these programs. These programs could be
adversely affected by a significant interruption in the supply of
active pharmaceutical ingredients and formulated drugs.</p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
<b>8. 401(k) Plan</b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
The Company has a 401(k) plan available for participating employees
who meet certain eligibility requirements. Eligible employees may
defer a portion of their salary as defined by the plan. Company
contributions to the plan may be made at the discretion of the
Board of Directors. To date, the Company has not made any
contributions to the plan.</p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<b><i>Fair Value Measurements</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
Certain assets and liabilities are carried at fair value under
GAAP. Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit
price) in the principal or most advantageous market for the asset
or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair
value must maximize the use of observable inputs and minimize the
use of unobservable inputs. Financial assets and liabilities
carried at fair value are to be classified and disclosed in one of
the following three levels of the fair value hierarchy, of which
the first two are considered observable and the last is considered
unobservable:</p>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="9%"> </td>
<td valign="top" width="3%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">Level 1—Quoted prices in active
markets for identical assets or liabilities.</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="9%"> </td>
<td valign="top" width="3%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">Level 2—Observable inputs
(other than Level 1 quoted prices) such as quoted prices in active
markets for similar assets or liabilities, quoted prices in markets
that are not active for identical or similar assets or liabilities,
or other inputs that are observable or can be corroborated by
observable market data.</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="9%"> </td>
<td valign="top" width="3%" align="left">•</td>
<td valign="top" width="1%"> </td>
<td valign="top" align="left">Level 3—Unobservable inputs
that are supported by little or no market activity and that are
significant to determining the fair value of the assets or
liabilities, including pricing models, discounted cash flow
methodologies and similar techniques.</td>
</tr>
</table>
<p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
The Company’s cash equivalents of $91,311 and $1,311 as of
September 30, 2014 and December 31, 2013, respectively,
were carried at fair value based on Level 2 inputs. The carrying
values of accounts payable and accrued expenses approximate their
fair value due to the short-term nature of these liabilities.</p>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
The Company recorded stock-based compensation expense related to
stock options and restricted common stock in the following expense
categories of its statements of operations:</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 </p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"><!-- Begin Table Head -->
<tr>
<td width="75%"></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months<br />
Ended<br />
September 30,</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months<br />
Ended<br />
September 30,</b></td>
<td valign="bottom"> </td>
</tr>
<tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
<td valign="bottom"> </td>
<td valign="bottom">  </td>
<td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
<td valign="bottom"> </td>
</tr>
<!-- End Table Head --><!-- Begin Table Body -->
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
Research and development</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">186</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">14</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">322</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">55</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<td valign="top">
<p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
General and administrative</p>
</td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">993</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">33</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">1,197</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom">  </td>
<td valign="bottom"> </td>
<td valign="bottom" align="right">82</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
<td valign="top"></td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">1,179</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">47</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">1,519</td>
<td valign="bottom" nowrap="nowrap">  </td>
<td valign="bottom"><font style="FONT-SIZE: 8pt">  </font></td>
<td valign="bottom">$</td>
<td valign="bottom" align="right">137</td>
<td valign="bottom" nowrap="nowrap">  </td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: rgb(0,0,0) 3px double"> </p>
</td>
<td> </td>
</tr>
<!-- End Table Body --></table>
</div>
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
<b><i>Accounting for Stock-Based Compensation</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
The Company measures all stock options and other stock-based awards
granted to employees and directors at the fair value on the date of
the grant using the Black-Scholes option-pricing model. The fair
value of the awards is recognized as expense, net of estimated
forfeitures, over the requisite service period, which is generally
the vesting period of the respective award. The straight-line
method of expense recognition is applied to all awards with
service-only conditions, while the graded vesting method is applied
to all grants with both service and performance conditions.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
For stock-based awards granted to non-employees, compensation
expense is recognized over the period during which services are
rendered by such non-employees until completed. At the end of each
financial reporting period prior to completion of the service, the
fair value of these awards is remeasured using the then-current
fair value of the Company’s common stock and updated
assumption inputs in the Black-Scholes option-pricing model.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
The Company classifies stock-based compensation expense in its
consolidated statement of operations and comprehensive loss in the
same manner in which the award recipient’s payroll costs are
classified or in which the award recipient’s service payments
are classified.</p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
The Company recognizes compensation expense for only the portion of
awards that are expected to vest. In developing a forfeiture rate
estimate, the Company has considered its historical experience to
estimate pre-vesting forfeitures for service-based awards. The
impact of a forfeiture rate adjustment will be recognized in full
in the period of adjustment, and if the actual forfeiture rate is
materially different from the Company’s estimate, the Company
may be required to record adjustments to stock-based compensation
expense in future periods.</p>
</div>
1974000
150000
113000
835000
21000
-17201000
113000
25000
-17088000
-17088000
1519000
1302000
17201000
1053000
10773000
73711000
16000
88547000
85345000
-23000
-175000
12000
361000
6428000
1884000
90396000
1519000
0
113000
6800000
<div>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
<b><i>Patent Costs</i></b></p>
<p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
All patent-related costs incurred in connection with filing and
prosecuting patent applications are recorded as general and
administrative expenses as incurred, as recoverability of such
expenditures is uncertain.</p>
</div>
2011
54604
972000
P30D
1852709
880000
100000
50000
10000
1197000
1053000
322000
8000
0
493299
-6.82
-3365000
-3365000
-3365000
47000
3365000
2704000
92000
661000
33000
14000
1000
218417
2357236
-2.71
-6424000
34000
-6390000
-6390000
1179000
6424000
2825000
152000
3599000
54604
880000
993000
186000
0
0001404281
us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
2014-07-01
2014-09-30
0001404281
us-gaap:ResearchAndDevelopmentExpenseMember
2014-07-01
2014-09-30
0001404281
us-gaap:GeneralAndAdministrativeExpenseMember
2014-07-01
2014-09-30
0001404281
us-gaap:PerformanceSharesMember
2014-07-01
2014-09-30
0001404281
us-gaap:RestrictedStockUnitsRSUMember
2014-07-01
2014-09-30
0001404281
2014-07-01
2014-09-30
0001404281
us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
2013-07-01
2013-09-30
0001404281
us-gaap:ResearchAndDevelopmentExpenseMember
2013-07-01
2013-09-30
0001404281
us-gaap:GeneralAndAdministrativeExpenseMember
2013-07-01
2013-09-30
0001404281
2013-07-01
2013-09-30
0001404281
tkai:FormerAdvisorMember
2013-01-01
2013-12-31
0001404281
us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
2014-01-01
2014-09-30
0001404281
us-gaap:ResearchAndDevelopmentExpenseMember
2014-01-01
2014-09-30
0001404281
us-gaap:GeneralAndAdministrativeExpenseMember
2014-01-01
2014-09-30
0001404281
tkai:UmbMemberus-gaap:PurchaseProvisionTermsMember
2014-01-01
2014-09-30
0001404281
tkai:UmbMembertkai:InvestigationalDrugApplicationMemberus-gaap:PurchaseProvisionTermsMember
2014-01-01
2014-09-30
0001404281
tkai:UmbMembertkai:NewDrugApplicationMemberus-gaap:PurchaseProvisionTermsMember
2014-01-01
2014-09-30
0001404281
us-gaap:PerformanceSharesMember
2014-01-01
2014-09-30
0001404281
us-gaap:StockOptionMember
2014-01-01
2014-09-30
0001404281
us-gaap:OverAllotmentOptionMember
2014-01-01
2014-09-30
0001404281
us-gaap:RestrictedStockUnitsRSUMember
2014-01-01
2014-09-30
0001404281
2014-01-01
2014-09-30
0001404281
us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
2013-01-01
2013-09-30
0001404281
us-gaap:ResearchAndDevelopmentExpenseMember
2013-01-01
2013-09-30
0001404281
us-gaap:GeneralAndAdministrativeExpenseMember
2013-01-01
2013-09-30
0001404281
tkai:UmbMemberus-gaap:LicenseAgreementTermsMember
2013-01-01
2013-09-30
0001404281
tkai:UmbMemberus-gaap:MinimumMemberus-gaap:RoyaltyAgreementTermsMember
2013-01-01
2013-09-30
0001404281
us-gaap:StockOptionMember
2013-01-01
2013-09-30
0001404281
us-gaap:RedeemableConvertiblePreferredStockMember
2013-01-01
2013-09-30
0001404281
us-gaap:RestrictedStockUnitsRSUMember
2013-01-01
2013-09-30
0001404281
2013-01-01
2013-09-30
0001404281
tkai:TwoThousandFourteenEmployeeStockPurchasePlanMemberus-gaap:ScenarioForecastMember
2014-12-31
2015-01-01
0001404281
tkai:TwoThousandFourteenStockIncentivePlanMemberus-gaap:ScenarioForecastMember
2014-12-31
2015-01-01
0001404281
us-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember
2014-10-09
2014-10-09
0001404281
us-gaap:OverAllotmentOptionMemberus-gaap:SubsequentEventMember
2014-10-09
2014-10-09
0001404281
us-gaap:CommonStockMember
2014-09-22
2014-09-22
0001404281
us-gaap:CommonStockMemberus-gaap:IPOMember
2014-09-22
2014-09-22
0001404281
2014-09-22
2014-09-22
0001404281
2014-08-29
2014-08-29
0001404281
tkai:TwoThousandFourteenEmployeeStockPurchasePlanMemberus-gaap:ScenarioForecastMember
2015-01-01
0001404281
tkai:TwoThousandFourteenStockIncentivePlanMemberus-gaap:ScenarioForecastMember
2015-01-01
0001404281
tkai:TwoThousandAndSevenStockIncentivePlanMember
2013-12-31
0001404281
tkai:UmbMemberus-gaap:PurchaseProvisionTermsMember
2013-12-31
0001404281
us-gaap:IPOMember
2013-12-31
0001404281
us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel2Member
2013-12-31
0001404281
2013-12-31
0001404281
2012-12-31
0001404281
us-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember
2014-10-09
0001404281
tkai:TwoThousandAndSevenStockIncentivePlanMember
2014-09-30
0001404281
tkai:TwoThousandFourteenStockIncentivePlanMember
2014-09-30
0001404281
tkai:UmbMemberus-gaap:PurchaseProvisionTermsMember
2014-09-30
0001404281
us-gaap:LicenseAgreementTermsMember
2014-09-30
0001404281
us-gaap:IPOMember
2014-09-30
0001404281
us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel2Member
2014-09-30
0001404281
2014-09-30
0001404281
us-gaap:CommonStockMemberus-gaap:IPOMember
2014-09-22
0001404281
tkai:TwoThousandFourteenStockIncentivePlanMember
2014-08-31
0001404281
tkai:TwoThousandFourteenStockIncentivePlanMemberus-gaap:MaximumMember
2014-08-31
0001404281
2013-09-30
0001404281
2014-11-10
0001404281
tkai:TwoThousandFourteenEmployeeStockPurchasePlanMember
2014-08-29
shares
iso4217:USD
iso4217:USD
shares
tkai:Amendments
pure